A Community-Based Study of Stroke Incidence after Myocardial Infarction

Brandi J. Witt; Robert D. Brown; Steven J. Jacobsen; Susan A. Weston; Barbara P. Yawn; Véronique L. Roger

doi:10.7326/0003-4819-143-11-200512060-00006

Abstract

Background:

The rate of stroke after myocardial infarction (MI) remains unclear.

Objectives:

To examine the rate of stroke after incident MI; compare it with that observed in the population of Rochester, Minnesota; determine how the rate of stroke after MI has changed over time; and examine the impact of stroke on survival after incident MI.

Design:

Community-based cohort.

Setting:

Olmsted County, Minnesota.

Participants:

Persons with incident (first-ever) MI between 1979 and 1998.

Measurements:

Ischemic or hemorrhagic stroke in hospitalized and nonhospitalized patients that was identified by screening of the medical record for stroke diagnostic codes and subsequent stroke confirmation by physician review of the recorded event. Medical record review was used to ascertain baseline characteristics and death.

Results:

A total of 2160 persons with incident MI were hospitalized between 1979 and 1998 and followed for a median of 5.6 years (range, 0 to 22.2 years). The rate of stroke was 22.6 per 1000 person-months (95% CI, 16.3 to 30.6 per 1000 person-months) during the first 30 days after MI, corresponding to a 44-fold increase (standardized morbidity ratio, 44 [95% CI, 32 to 59]) risk for stroke in the population of Rochester, Minnesota. The risk for stroke remained 2 to 3 times higher than expected during the first 3 years after MI. Older age, previous stroke, and diabetes increased the risk for stroke, which did not decline over the study period. Strokes were associated with a large increase in the risk for death after MI (hazard ratio, 2.89 [CI, 2.44 to 3.43]).

Limitations:

Findings may not be generalizable to different populations. The authors measured outcomes by reviewing medical records.

Conclusions:

In the community, the risk for stroke is markedly increased after MI, particularly early after MI, compared with the expected risk in population without MI. Stroke is associated with a large increase in the risk for death after MI.

Editors’ Notes

Context

After a myocardial infarction (MI), outcomes such as heart failure and recurrent MI are decreasing. What about stroke?

Contribution

This cohort study from Olmsted County, Minnesota, had a 44-fold increase in stroke rate during the first month after MI compared with the stroke rate in the general community. Stroke rates in the cohort declined markedly after the first month but exceeded the rates in the general community for 3 years. Strokes after MI were associated with increased risk for death, and their rate did not decline between 1979 and 1998.

Implications

Early after MI, risk for stroke is markedly increased. This risk has not declined over time.

—The Editors

Coronary disease is the leading cause of death in the United States, and stroke is the third leading cause of death and the most common cause of disability (1). Both diseases share common risk factors (2-7) and treatments, such as antihypertensive agents, lipid-lowering agents, and aspirin (8, 9). Because the incidence of myocardial infarction (MI) is stabilizing and survival after MI is improving (10, 11), understanding the burden of morbidity after MI and how it may be changing over time becomes increasingly important in caring for the growing population of survivors. Several investigators, including our group, have reported declining recurrence of MI and heart failure after incident MI (10, 12-16). However, less is known about stroke after MI. Most studies that have reported rates of stroke after MI focused on short-term events that occurred during the patient's hospital stay or within the first month after MI. They often addressed the question within the framework of clinical trials, which may not be fully representative of the experience of the community. Finally, the reported rate of stroke early after MI is difficult to interpret because of the lack of an appropriate reference population.

This study was done to address these gaps in knowledge by examining, in a geographically defined population, the rate of stroke after MI over a comprehensive period of observation. We included data not only from the first month after MI but also for several years afterward, within a rigorously characterized longitudinal MI incidence cohort spanning 2 decades. Specifically, we evaluated the excess risk for stroke that MI confers compared with that in the general population, the secular trends in the occurrence of stroke after MI, factors predictive of stroke after MI, and the impact of stroke on survival post-MI.

Methods

Study Setting

This study was conducted in Olmsted County, Minnesota, where residents receive medical care at a small number of facilities, including the Mayo Clinic. The characteristics of the study population mainly reflected those of U.S. white persons. The Rochester Epidemiology Project (17), a medical record linkage system, enables access to all aspects of an individual patient's records from all sites in Olmsted County. These comprehensive medical records allow the study of diseases over a prolonged period as they occur in an unselected, geographically defined population without many of the biases inherent in tertiary care settings. The appropriate institutional review boards approved all aspects of the study.

Identification of the Study Cohort

The procedures used to assemble the MI incidence cohort have been described previously (11). Briefly, all persons discharged from county hospitals between 1979 and 1998 with codes compatible with an MI were identified. The following target codes were included from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM): 410 (acute MI), 411 (other acute and subacute forms of ischemic heart disease), 412 (old MI), 413 (angina pectoris), and 414 (other forms of ischemic heart disease). All events coded 410 and samples of events coded 411 through 414 were reviewed (11). Trained abstractors verified patients' residency status in Olmsted County and incident status of MI by complete review of the medical record and collected information on the presence of cardiac pain, creatine kinase values, and electrocardiograms, which were assigned a Minnesota Code by the Electrocardiogram Reading Center at the University of Minnesota (18). Standard criteria were applied to assign the diagnosis of MI on the basis of cardiac pain, enzyme values, and Minnesota Code. Comorbidity was measured by the Charlson index, a validated measure of comorbidity (19). Reperfusion therapy was defined as thrombolysis or percutaneous coronary intervention that was done during the hospitalization. Atrial fibrillation was recorded at any time during the patients' medical histories before the stroke occurred.

In the Rochester Stroke Registry (20), all residents of Rochester, Minnesota, who had stroke diagnoses identified through the Rochester Epidemiology Project are validated by physician review and entered in the Registry. The ICD-9-CM codes used for case ascertainment include codes 430 through 438 (cerebrovascular disease), 781.4 (transient paralysis of a limb), 784.3 (aphasia), 362.34 (transient arterial occlusion, amaurosis fugax), and 368.12 (transient visual loss). Because the MI incidence cohort includes all of Olmsted County and the Stroke Registry includes only residents of the city of Rochester, there is incomplete overlap between the 2 registries. Thus, all strokes occurring before July 2003 in residents of Olmsted County that were not included in the Stroke Registry were identified by using the same aforementioned diagnostic codes and were validated by physician review.

Stroke Definitions

To avoid temporal changes in the ascertainment of stroke related to changes in imaging techniques and to be certain of the timing of stroke, strokes without a corresponding clinical event that were found only on imaging of the patient's head (computed tomography [CT] or magnetic resonance imaging [MRI]) or at autopsy were not included. Transient ischemic attacks defined as focal neurologic symptoms lasting less than 24 hours; traumatic subdural hematoma; hemorrhage into abnormal tissue, such as tumor or inflammation; and isolated infarction of the retina, labyrinth, or cochlea were excluded.

Cerebral infarction was defined as the acute onset (minutes to hours) of a focal neurologic deficit persisting more than 24 hours, with or without CT or MRI documentation, and caused by altered circulation to a limited region of the cerebral hemispheres, brainstem, or cerebellum. Findings on CT, MRI, or autopsy (if available) did not show evidence of intracerebral hemorrhage.

Intracerebral hemorrhage was defined as the acute onset of a focal neurologic deficit associated with some or all of the following: headache, vomiting, altered level of consciousness, signs of meningeal irritation, or blood-stained cerebrospinal fluid. If done, CT, MRI, or autopsy showed a parenchymal hemorrhage.

Subarachnoid hemorrhage was defined as the abrupt onset of headache, with or without altered consciousness, with signs of meningeal irritation. A focal deficit may have developed acutely or with a delay of hours or days. Computed tomography, MRI, or examinations of cerebrospinal fluid examinations showed blood in the subarachnoid space.

Strokes were classified as “hospitalized strokes” if a hospital admission for stroke or stroke-related complications occurred within 30 days after the event. Follow-up was obtained by passive surveillance through community (inpatient and outpatient) medical records. More than 90% of the population of Olmsted County receives ongoing care at Mayo Clinic or Olmsted Medical Center, and 96% of residents are seen, on average, every 3 years at Mayo Clinic (17). Ascertainment of death included death certificates filed in Olmsted County, autopsy reports, obituary notices, and electronic files of death certificates obtained from the State of Minnesota Department of Vital and Health Statistics.

Quality Control

The reliability of MI ascertainment has been reported previously (11) and indicates excellent interabstractor agreement. For stroke ascertainment, the study neurologist, in addition to the principal investigator, reviewed a sample of 25 randomly selected potential cases, of which 16 were ischemic strokes, 1 was a hemorrhagic stroke, and 8 were nonstrokes. The interobserver variability showed excellent agreement (κ = 0.93; 95% CI, 0.79 to 1.00) between the 2 physicians, indicating excellent reliability for the ascertainment of stroke. Furthermore, previous work from our center indicated that the case-finding approach used in the current study yielded results similar to those reported for a cohort approach confirming the robustness of our method of ascertainment (20).

Statistical Analysis

The rate of stroke after MI was examined for all strokes (first and recurrent) and for incident (first-ever) strokes and was expressed per 1000 person-months. The incident stroke rate after MI was compared with the incident stroke rate in the population of Rochester, Minnesota, by using data from the Rochester Stroke Registry (21) to calculate standardized morbidity ratios. Expected stroke rates were calculated by applying sex-, age-, and period-specific stroke rates in the general population of Rochester to the person-time follow-up of the study population. The standardized morbidity ratio was calculated by dividing the number of observed strokes by the expected number of strokes over the duration of follow-up. Confidence intervals were calculated according to the Poisson distribution.

Proportional hazards regression was used to examine associations between patient characteristics and the occurrence of a stroke after MI and to examine the association between stroke and death after MI while adjusting for age, sex, Killip class, aspirin use, and warfarin use; stroke was analyzed as a time-dependent covariate. The correlation of the scaled Schoenfeld residuals with time was used to test the proportional hazards assumption. Except for family history of coronary artery disease (7.2%), anterior MI (15.8%), ST-segment elevation MI (12.8%), and presence of Q waves (21%), missing values did not exceed 5%. Because ST-segment elevation and presence of Q waves are both surrogates for MI severity, we elected to use peak creatine kinase ratio, defined as the ratio of the maximum creatine kinase value to the upper limit of normal, as the measure of MI severity. The peak creatine kinase ratio was missing in less than 5% of the observations. Fewer than 2% of persons had 1 or more missing variables for the predictors in the final multivariable models. Because the proportional hazards assumption was not met, strokes were divided into early strokes (occurring ≤ 30 days after MI) and late strokes (occurring > 30 days after MI). For late strokes, the proportional hazards assumption was met for all predictor variables (P > 0.05 for all variables). Results are reported as hazard ratios with 95% CIs. Analyses were done using the statistical software package SAS, version 8.2 (SAS Institute Inc., Cary, North Carolina).

Role of the Funding Source

The funding source supported the data collection, data analysis, and manuscript preparation.

Results

Baseline Characteristics

Between 1979 and 1998, 2171 Olmsted County residents were hospitalized with incident MI. Stroke could not be ascertained as an outcome in 11 patients, resulting in a cohort of 2160 persons. The mean age (SD) at the date of index MI was 67 years (SD, 14), and 57% of the patients were men. Fifty-six percent of the patients had a history of hypertension, and 65% were current or former smokers. One hundred eighty-eight (9%) had a stroke before the index MI. Nearly all strokes that occurred before the MI were ischemic (174 [93%]), and the remaining 7% consisted of 7 intracerebral hemorrhages and 7 subarachnoid hemorrhages.

Occurrence of Stroke after MI

During a median follow-up of 5.6 years (range, 0 to 22.2 years), there were 273 strokes, of which 259 (95%) were ischemic; the remaining 5% consisted of 13 intracerebral hemorrhages and 1 subarachnoid hemorrhage. Eighty-three percent of the patients were hospitalized for evaluation within 30 days of the stroke. The occurrence of stroke was not equally distributed during the follow-up period; a large proportion of the strokes (18%) occurred within 30 days of the index MI followed by a gradual decline thereafter.

Table 1 shows the rates per 1000 person-months for all strokes (first and recurrent) and for incident (first-ever) strokes for the duration of follow-up. The rate was the highest during the first 30 days after MI, at 23.9 per 1000 person-months (CI, 17.6 to 31.6 per 1000 person-months) for all strokes, equating to 2.3% of all patients with MI. When only incident strokes after MI were considered, the observed rate of incident strokes during the first 30 days was 22.6 per 1000 person-months (CI, 16.3 to 30.6 per 1000 person-months). Compared with the expected rate, this represents a 44-fold increase in the risk for stroke (standardized morbidity ratio, 44 [CI, 32 to 59]).

Table 1. Rate of Stroke after Myocardial Infarction in Olmsted County, Minnesota

In the second month of follow-up, the stroke rate declined to 2.3 per 1000 person-months without additional change during the remainder of the first year. The risk for stroke declined gradually as time from the index MI increased but remained 2 to 3 times higher than the expected rate during the 3 years after MI. Beyond year 3, the risk for stroke was no longer different from that in the general population of Rochester. The dynamic nature of the excess risk for stroke after MI is shown in the Figure, which depicts the gradual decline over time of the observed versus expected strokes (standardized morbidity ratio) from the time of the index MI throughout the follow-up.

Figure.

Ratio of observed strokes in the myocardial infarction (MI) cohort to expected strokes in Rochester, Minnesota (standardized morbidity ratio [SMR]).

The risk for stroke after MI did not decline in patients with more recent MIs. During the first decade of the study, after adjustment for age and sex, the risk for stroke increased by 74% (hazard ratio for stroke after an MI occurring in 1988 compared with that after an MI occurring in 1979, 1.74 [CI, 1.12 to 2.71]; P = 0.015). During the second decade, no additional change in the risk for stroke after MI was detected (hazard ratio for stroke after an MI occurring in 1998 compared with that after an MI occurring in 1988, 0.87 [CI, 0.54 to 1.41]; P = 0.57). The results were unchanged after adding previous stroke, hypertension, diabetes, smoking, hyperlipidemia, and obesity to the model.

Characteristics Associated with Stroke after Incident MI

Older age, female sex, greater comorbidity, hypertension, diabetes, atrial fibrillation, Killip class, and previous stroke were all univariately associated with stroke after MI (Table 2). No association was seen between stroke and peak creatine kinase ratio, location of MI, presence of Q waves, or ST-segment elevation. Regarding thrombolysis, there was no clinically significant difference between patients who had a stroke and those who did not, although patients who had a stroke were less likely to receive percutaneous coronary intervention.

Table 2. Characteristics of Patients with Myocardial Infarction by Occurrence of Stroke

When entered in a multivariable model, the factors independently associated with stroke after MI included older age (hazard ratio, 1.04 per year [CI, 1.03 to 1.05 per year]; P < 0.001); history of stroke (hazard ratio, 2.07 [CI, 1.44 to 2.97]; P < 0.001); and diabetes mellitus (hazard ratio, 1.68 [CI, 1.27 to 2.20]; P < 0.001). Adjusting for the use of aspirin, β-blockers, angiotensin-converting enzyme inhibitors, statins, calcium-channel blockers, or diuretics at admission or at discharge did not change the results, nor did we detect an interaction between hypertension and any of these medications (data not shown). Because of the markedly higher excess risk for stroke early after MI, exploratory analyses were conducted to examine whether the association between any clinical variable and stroke differed by the timing of the stroke. Persons who had a stroke early after MI were older than those who had a stroke later (P < 0.001) and had a larger MI as measured by peak creatine kinase ratio (P = 0.030).

Survival after Stroke

At 1 year, follow-up was 99% complete and 402 patients had died. Patients who had a stroke at any time during follow-up had a markedly increased risk for death compared with patients who did not have a stroke (Table 3). Indeed, stroke was associated with a 2- to 3-fold increase in the risk for death, independent of age, sex, and Killip class. Similar results were found after adjusting for aspirin and warfarin use.

Table 3. Risk for Death after Myocardial Infarction Associated with Stroke

Discussion

Patients with MI have a high risk for strokes, most of which are ischemic. The risk for stroke after MI is dynamic and declines as time from the index MI increases. However, the risk for stroke after MI did not decline during the 2 decades of the study period. The excess risk for stroke after MI is considerable compared with that expected in a population without MI, particularly in the first month after MI. The devastating impact of stroke after MI on survival and the increasing number of persons at risk because of improved survival constitute an important public health matter for persons with coronary disease.

Risk for Stroke after MI

Most studies considered strokes during the initial hospital admission for the MI or the first month thereafter and reported rates ranging between 0.75% and 4.6% (2, 4, 6,7, 22-34). However, most of these are clinical trials that are not comparable with our study. Among cohort studies, stroke rates ranged from 1.1% to 1.5% in the first 30 days after MI (4, 35, 36). Several methodologic issues limit the inferences that can be made from these studies. These issues include, in particular, the exclusion of elderly individuals, the lack of long-term follow-up, reliance of the study design on registries from trials or national surveys, and small sample size.

Data on long-term risk for stroke after MI are also sparse. Stroke rates range from 3% at 6 months to 8.6% at 10 years after MI (22, 37-46). As is the case for studies reporting short-term stroke rates, many of these are clinical trials. Cohort studies providing long-term data are limited because they identified survivors through administrative databases (39) or through billing records (43). Also, they did not provide information on the background stroke rates in a similar population, except for 1 report from the Monitoring of Cardiovascular Disease (MONICA) study, where the rate of stroke within 28 days after MI was markedly higher than that expected in the general study population (4). This study, however, did not include older persons. Thus, our data extend these findings by including participants of all ages and providing a comparison population, which is essential to understand the magnitude of the excess risk for stroke conferred by MI. Finally, temporal trends in the risk for stroke after MI remain largely unknown with the exception of data from the Worcester Heart Attack Study, which suggested an increase in the risk for in-hospital stroke with time but lacked information about long-term follow-up (35).

As a result of these limitations, the magnitude and the dynamic nature of the risk for stroke after MI have not previously been recognized. Our study addresses this important gap in knowledge by showing that, within this geographically defined population, using rigorous definitions for MI and stroke and including strokes in patients who were not hospitalized, the observed rate of incident stroke after MI is high, largely exceeding that expected in a population without MI. Also, the risk for stroke after MI is dynamic and is markedly elevated early after MI. Indeed, compared with the expected incidence of stroke, the excess risk observed within 30 days after MI corresponds to a 44-fold increased risk for stroke. During the 2 decades of the study, no reduction in this risk was detected; however, an increase was apparent during the first decade with stabilization thereafter. These data suggest that contemporary management strategies for MI have not affected the subsequent risk for stroke compared with older therapies.

Predictors of Stroke after MI

Factors independently associated with an increased risk for stroke included older age, history of stroke, and diabetes, all of which are traditionally associated with stroke in the general population. However, the timing of stroke in relation to MI suggests that conventional cardiovascular risk factors do not fully explain the marked increase in the risk for stroke early after MI. Regarding acute treatment of MI, meta-analyses of the randomized trials of thrombolysis in acute MI eased the concern that thrombolysis increased the risk for stroke considerably (47, 48). Our study extends these reports by indicating that the rate of hemorrhagic stroke after MI in the community is low. Also, the stabilization of the rate of stroke in the second decade of the study, corresponding to the “thrombolytic era,” suggests that the use of thrombolytics, which increased over that period (49), did not coincide with an increase in hemorrhagic stroke.

The association between the size and severity of the MI and stroke remains controversial. Some authors suggest that severity is related to stroke (3, 4, 7, 25), whereas others failed to detect such an association. Our analyses suggest that larger size is associated with early occurrence of stroke after MI. Finally, the timing of the stroke in relation to the MI suggests that systemic inflammation, which plays an increasingly recognized role in MI and stroke, may partly explain the marked increase in the risk for stroke during the early period after MI (50).

Implications

These results have important implications. Our findings contrast with trends in cardiac outcomes after MI, such as heart failure (12) and recurrent MI (16, 51-53), which are declining over time. Stroke conversely exhibits no temporal decline, and therefore our data constitute proof of concept that the current therapies for acute MI do not confer adequate protection against stroke, particularly in the early phase after MI. The use of oral anticoagulation after acute MI remains controversial, despite increasing evidence that suggests a potential benefit in stroke prevention (48, 54, 55), because of the concern that the risk for bleeding associated with warfarin use outweighs its benefit. Notwithstanding this valid concern, our data suggest that the use of antithrombotic measures relying on different agents should be revisited. Our documentation of the dynamic nature of the risk for stroke after MI can further assist in determining the appropriate duration of such therapies. The strong association between stroke and death further underscores the need to aggressively pursue preventive approaches.

Several synergistic factors contribute to the increase in the absolute number of strokes after MI, including the increase in the number of MI survivors and the increased prevalence of 2 chief characteristics associated with stroke, namely older age and diabetes mellitus. These factors, along with the increased awareness of the importance of morbidity after MI in the growing and aging population of survivors of MI (56), indicate that increased attention should be dedicated to devising more effective stroke prevention strategies.

Limitations

The risk for stroke has increased in black and Hispanic persons (57). Although the population of Olmsted County is becoming more diverse, the population during the study period consisted primarily of U.S. white persons. Thus, these findings should be reexamined in different racial and ethnic groups. We do not have information on the distribution of follow-up visits after MI and could only match the comparison population on the risk factors of age, sex, and year of diagnosis. Thus, we could not determine the proportion of the excess risk for stroke associated with MI that might be explained by traditional risk factors or MI alone. The observational design of our study did not allow us to determine whether anticoagulant or antiplatelet medications were prescribed to treat or to prevent stroke after MI, limiting our ability to draw conclusions regarding the use of such medications and stroke risk. Although subtyping of ischemic strokes in our cohort is not available, its impact on analysis would probably be minimal; many early strokes would have been classified as cardioembolic, because of their temporal association to the MI (58).

Conclusions

These data from a geographically defined population indicate that patients with MI have a high risk for stroke, which is not declining as treatment for MI improves. The excess risk for stroke after MI compared with that expected in a population without MI is considerable, particularly in the early phase. It is also dynamic and declines as time from the index MI increases. The devastating impact of stroke on survival and the increased number of patients at risk because of improved survival after MI constitute an important public health matter for persons with coronary disease.

References

American Heart Association/American College of Cardiology. Heart and Stroke Statistical Update. Vol. 2004; 2004. Accessed at www.americanheart.org on 10 October 2005.
Maggioni
AP
,
Franzosi
MG
,
Santoro
E
,
White
H
,
Van de Werf
F
,
Tognoni
G
.
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
N Engl J Med
1992
327
1
6
PubMed
CrossRef
PubMed
Tanne
D
,
Reicher-Reiss
H
,
Boyko
V
,
Behar
S
.
Stroke risk after anterior wall acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial.
Am J Cardiol
1995
76
825
6
PubMed
CrossRef
PubMed
Mooe
T
,
Eriksson
P
,
Stegmayr
B
.
Ischemic stroke after acute myocardial infarction. A population-based study.
Stroke
1997
28
762
7
PubMed
CrossRef
PubMed
Bodenheimer
MM
,
Sauer
D
,
Shareef
B
,
Brown
MW
,
Fleiss
JL
,
Moss
AJ
.
Relation between myocardial infarct location and stroke.
J Am Coll Cardiol
1994
24
61
6
PubMed
CrossRef
PubMed
Longstreth
WT
Jr
,
Litwin
PE
,
Weaver
WD
.
Myocardial infarction, thrombolytic therapy, and stroke. A community-based study. The MITI Project Group.
Stroke
1993
24
587
90
PubMed
CrossRef
PubMed
O'Connor
CM
,
Califf
RM
,
Massey
EW
,
Mark
DB
,
Kereiakes
DJ
,
Candela
RJ
.
et al
Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis.
J Am Coll Cardiol
1990
16
533
40
PubMed
CrossRef
PubMed
Ryan
TJ
,
Antman
EM
,
Brooks
NH
,
Califf
RM
,
Hillis
LD
,
Hiratzka
LF
.
et al
1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).
Circulation
1999
100
1016
30
PubMed
CrossRef
PubMed
Goldstein
LB
,
Adams
R
,
Becker
K
,
Furberg
CD
,
Gorelick
PB
,
Hademenos
G
.
et al
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.
Circulation
2001
103
163
82
PubMed
CrossRef
PubMed
Rosamond
WD
,
Chambless
LE
,
Folsom
AR
,
Cooper
LS
,
Conwill
DE
,
Clegg
L
.
et al
Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.
N Engl J Med
1998
339
861
7
PubMed
CrossRef
PubMed
Roger
VL
,
Jacobsen
SJ
,
Weston
SA
,
Goraya
TY
,
Killian
J
,
Reeder
GS
.
et al
Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994.
Ann Intern Med
2002
136
341
8
CrossRef
PubMed
Hellermann
JP
,
Goraya
TY
,
Jacobsen
SJ
,
Weston
SA
,
Reeder
GS
,
Gersh
BJ
.
et al
Incidence of heart failure after myocardial infarction: is it changing over time?
Am J Epidemiol
2003
157
1101
7
PubMed
CrossRef
PubMed
Goldberg
RJ
,
Yarzebski
J
,
Lessard
D
,
Gore
JM
.
A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective.
J Am Coll Cardiol
1999
33
1533
9
PubMed
CrossRef
PubMed
Sytkowski
PA
,
D'Agostino
RB
,
Belanger
A
,
Kannel
WB
.
Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989.
Am J Epidemiol
1996
143
338
50
PubMed
CrossRef
PubMed
McGovern
PG
,
Jacobs
DR
Jr
,
Shahar
E
,
Arnett
DK
,
Folsom
AR
,
Blackburn
H
.
et al
Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey.
Circulation
2001
104
19
24
PubMed
CrossRef
PubMed
Jokhadar
M
,
Jacobsen
SJ
,
Reeder
GS
,
Weston
SA
,
Roger
VL
.
Sudden death and recurrent ischemic events after myocardial infarction in the community.
Am J Epidemiol
2004
159
1040
6
PubMed
CrossRef
PubMed
Melton
LJ
3rd
.
History of the Rochester Epidemiology Project.
Mayo Clin Proc
1996
71
266
74
PubMed
CrossRef
PubMed
Prineas
R
,
Crow
R
,
Blackburn
H
.
The Minnesota Code Manual of Electrocardiographic Findings.
Littleton, MA
John Wright-PSG Inc
1982
Charlson
ME
,
Pompei
P
,
Ales
KL
,
MacKenzie
CR
.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
1987
40
373
83
PubMed
CrossRef
PubMed
Whisnant
JP
,
Melton
LJ
3rd
,
Davis
PH
,
O'Fallon
WM
,
Nishimaru
K
,
Schoenberg
BS
.
Comparison of case ascertainment by medical record linkage and cohort follow-up to determine incidence rates for transient ischemic attacks and stroke.
J Clin Epidemiol
1990
43
791
7
PubMed
CrossRef
PubMed
Brown
RD
,
Whisnant
JP
,
Sicks
JD
,
O'Fallon
WM
,
Wiebers
DO
.
Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989.
Stroke
1996
27
373
80
PubMed
PubMed
Wienbergen
H
,
Schiele
R
,
Gitt
AK
,
Schneider
S
,
Heer
T
,
Gottwik
M
.
et al
Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice. MIR and MITRA Study Groups. Myocardial Infarction Registry. Maximal Individual Therapy in Acute Myocardial Infarction.
Am J Cardiol
2001
87
782
5, A8
PubMed
CrossRef
PubMed
Gore
JM
,
Sloan
M
,
Price
TR
,
Randall
AM
,
Bovill
E
,
Collen
D
.
et al
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Circulation
1991
83
448
59
PubMed
CrossRef
PubMed
Gore
JM
,
Granger
CB
,
Simoons
ML
,
Sloan
MA
,
Weaver
WD
,
White
HD
.
et al
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.
Circulation
1995
92
2811
8
PubMed
CrossRef
PubMed
Thompson
PL
,
Robinson
JS
.
Stroke after acute myocardial infarction: relation to infarct size.
Br Med J
1978
2
457
9
PubMed
CrossRef
PubMed
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
Lancet
1992
339
753
70
PubMed
CrossRef
PubMed
Kandzari
DE
,
Granger
CB
,
Simoons
ML
,
White
HD
,
Simes
J
,
Mahaffey
KW
.
et al
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Am J Cardiol
2004
93
458
61
PubMed
CrossRef
PubMed
Stone
GW
,
Grines
CL
,
Cox
DA
,
Garcia
E
,
Tcheng
JE
,
Griffin
JJ
.
et al
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
N Engl J Med
2002
346
957
66
PubMed
CrossRef
PubMed
Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.
Eur Heart J
2000
21
2005
13
PubMed
CrossRef
PubMed
Cannon
CP
,
McCabe
CH
,
Wilcox
RG
,
Langer
A
,
Caspi
A
,
Berink
P
.
et al
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Circulation
2000
102
149
56
PubMed
CrossRef
PubMed
Steg
PG
,
Bonnefoy
E
,
Chabaud
S
,
Lapostolle
F
,
Dubien
PY
,
Cristofini
P
.
et al
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
Circulation
2003
108
2851
6
PubMed
CrossRef
PubMed
Sutton
AG
,
Campbell
PG
,
Graham
R
,
Price
DJ
,
Gray
JC
,
Grech
ED
.
et al
A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial.
J Am Coll Cardiol
2004
44
287
96
PubMed
CrossRef
PubMed
Andersen
HR
,
Nielsen
TT
,
Rasmussen
K
,
Thuesen
L
,
Kelbaek
H
,
Thayssen
P
.
et al
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.
N Engl J Med
2003
349
733
42
PubMed
CrossRef
PubMed
de Boer
MJ
,
Ottervanger
JP
,
van't Hof
AW
,
Hoorntje
JC
,
Suryapranata
H
,
Zijlstra
F
.
et al
Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy.
J Am Coll Cardiol
2002
39
1723
8
PubMed
CrossRef
PubMed
Spencer
FA
,
Gore
JM
,
Yarzebski
J
,
Lessard
D
,
Jackson
EA
,
Goldberg
RJ
.
Trends (1986 to 1999) in the incidence and outcomes of in-hospital stroke complicating acute myocardial infarction (The Worcester Heart Attack Study).
Am J Cardiol
2003
92
383
8
PubMed
CrossRef
PubMed
Brodie
BR
,
Stuckey
TD
,
Hansen
CJ
,
VerSteeg
D
,
Muncy
D
,
Pulsipher
M
.
et al
Effect of treatment delay on outcomes in patients with acute myocardial infarction transferred from community hospitals for primary percutaneous coronary intervention.
Am J Cardiol
2002
89
1243
7
PubMed
CrossRef
PubMed
Aversano
T
,
Aversano
LT
,
Passamani
E
,
Knatterud
GL
,
Terrin
ML
,
Williams
DO
.
et al
Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized, controlled trial.
JAMA
2002
287
1943
51
PubMed
CrossRef
PubMed
Schömig
A
,
Kastrati
A
,
Dirschinger
J
,
Mehilli
J
,
Schricke
U
,
Pache
J
.
et al
Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
N Engl J Med
2000
343
385
91
PubMed
CrossRef
PubMed
Lichtman
JH
,
Krumholz
HM
,
Wang
Y
,
Radford
MJ
,
Brass
LM
.
Risk and predictors of stroke after myocardial infarction among the elderly: results from the Cooperative Cardiovascular Project.
Circulation
2002
105
1082
7
PubMed
CrossRef
PubMed
Nikolsky
E
,
Aymong
ED
,
Halkin
A
,
Grines
CL
,
Cox
DA
,
Garcia
E
.
et al
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
J Am Coll Cardiol
2004
44
547
53
PubMed
CrossRef
PubMed
O'Connor
CM
,
Gattis
WA
,
Hellkamp
AS
,
Langer
A
,
Larsen
RL
,
Harrington
RA
.
et al
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
Am J Cardiol
2001
88
541
6
PubMed
CrossRef
PubMed
Minai
K
,
Horie
H
,
Takahashi
M
,
Nozawa
M
,
Kinoshita
M
.
Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial.
Am Heart J
2002
143
497
505
PubMed
CrossRef
PubMed
Kaplan
RC
,
Heckbert
SR
,
Furberg
CD
,
Psaty
BM
.
Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction.
J Clin Epidemiol
2002
55
654
64
PubMed
CrossRef
PubMed
Herlitz
J
,
Holm
J
,
Peterson
M
,
Karlson
BW
,
Evander
MH
,
Erhardt
L
.
et al
Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial.
J Intern Med
2005
257
201
7
PubMed
CrossRef
PubMed
Lee
CD
,
Folsom
AR
,
Pankow
JS
,
Brancati
FL
.
Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction.
Circulation
2004
109
855
60
PubMed
CrossRef
PubMed
Wannamethee
SG
,
Shaper
AG
,
Lennon
L
.
Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease.
Heart
2004
90
1398
403
PubMed
CrossRef
PubMed
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.
Lancet
1994
343
311
22
PubMed
PubMed
Vaitkus
PT
,
Berlin
JA
,
Schwartz
JS
,
Barnathan
ES
.
Stroke complicating acute myocardial infarction. A meta-analysis of risk modification by anticoagulation and thrombolytic therapy.
Arch Intern Med
1992
152
2020
4
PubMed
CrossRef
PubMed
Perschbacher
JM
,
Reeder
GS
,
Jacobsen
SJ
,
Weston
SA
,
Killian
JM
,
Slobodova
A
.
et al
Evidence-based therapies for myocardial infarction: secular trends and determinants of practice in the community.
Mayo Clin Proc
2004
79
983
91
PubMed
CrossRef
PubMed
Lombardo
A
,
Biasucci
LM
,
Lanza
GA
,
Coli
S
,
Silvestri
P
,
Cianflone
D
.
et al
Inflammation as a possible link between coronary and carotid plaque instability.
Circulation
2004
109
3158
63
PubMed
CrossRef
PubMed
Guidry
UC
,
Evans
JC
,
Larson
MG
,
Wilson
PW
,
Murabito
JM
,
Levy
D
.
Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study.
Circulation
1999
100
2054
9
PubMed
CrossRef
PubMed
Heidenreich
PA
,
McClellan
M
.
Trends in treatment and outcomes for acute myocardial infarction: 1975-1995.
Am J Med
2001
110
165
74
PubMed
CrossRef
PubMed
McGovern
PG
,
Pankow
JS
,
Shahar
E
,
Doliszny
KM
,
Folsom
AR
,
Blackburn
H
.
et al
Recent trends in acute coronary heart disease—mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.
N Engl J Med
1996
334
884
90
PubMed
CrossRef
PubMed
Azar
AJ
,
Koudstaal
PJ
,
Wintzen
AR
,
van Bergen
PF
,
Jonker
JJ
,
Deckers
JW
.
Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction.
Ann Neurol
1996
39
301
7
PubMed
CrossRef
PubMed
Hurlen
M
,
Abdelnoor
M
,
Smith
P
,
Erikssen
J
,
Arnesen
H
.
Warfarin, aspirin, or both after myocardial infarction.
N Engl J Med
2002
347
969
74
PubMed
CrossRef
PubMed
Braunwald
E
.
Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.
N Engl J Med
1997
337
1360
9
PubMed
CrossRef
PubMed
Giles
WH
,
Kittner
SJ
,
Hebel
JR
,
Losonczy
KG
,
Sherwin
RW
.
Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study.
Arch Intern Med
1995
155
1319
24
PubMed
CrossRef
PubMed
Adams
HP
Jr
,
Bendixen
BH
,
Kappelle
LJ
,
Biller
J
,
Love
BB
,
Gordon
DL
.
et al
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke
1993
24
35
41
PubMed
CrossRef
PubMed

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Articles |6 December 2005

A Community-Based Study of Stroke Incidence after Myocardial Infarction Free

Abstract

Editors’ Notes

Context

Contribution

Implications

Methods

Study Setting

Identification of the Study Cohort

Stroke Definitions

Quality Control

Statistical Analysis

Role of the Funding Source

Results

Baseline Characteristics

Occurrence of Stroke after MI

Table 1. Rate of Stroke after Myocardial Infarction in Olmsted County, Minnesota

Figure.

Characteristics Associated with Stroke after Incident MI

Table 2. Characteristics of Patients with Myocardial Infarction by Occurrence of Stroke

Survival after Stroke

Table 3. Risk for Death after Myocardial Infarction Associated with Stroke

Discussion

Risk for Stroke after MI

Predictors of Stroke after MI

Implications

Limitations

Conclusions

References

Figure.

Table 1. Rate of Stroke after Myocardial Infarction in Olmsted County, Minnesota

Table 2. Characteristics of Patients with Myocardial Infarction by Occurrence of Stroke

Table 3. Risk for Death after Myocardial Infarction Associated with Stroke

Clinical Slide Sets

Video News Release - Heart Attack Patients Have High Risk for Stroke in First Month after Attack (1:34)

This feature is available only to Registered Users

0 Comments

See Also

Related Articles

Journal Club

Related Point of Care

Related Topics

PubMed Articles

Content

Information For

Services

Awards and Cover

Other Resources

Follow Annals On

You need a subscription to this content to use this feature.